Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Sensitisation data (human)

Currently viewing:

Administrative data

Endpoint:
sensitisation data (humans)
Type of information:
other: published data
Adequacy of study:
supporting study
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
abstract
Justification for type of information:
C12 LAS; Linear Alkylbenzene Sulfonate (LAS)) is a very close analogue of Calcium dodecylbenzenesulfonate (CAS No 26264-06-2, EC Number; 247-557-8) ) and read-across is valid.

Data source

Reference
Reference Type:
other company data
Title:
Unnamed
Year:
1997

Materials and methods

Type of sensitisation studied:
skin
Study type:
study with volunteers
Test guideline
Qualifier:
according to guideline
Guideline:
other: Human Repeat Insult Patch Test
Principles of method if other than guideline:
Human Repeat Insult Patch Test
Method:LAS was applied at 0.10% (w/v) on the upper arms of volunteers, under occlusive patch conditions. Test material was applied for 24 hours, 3 times a week, for 3 weeks during the induction period. After a 14-17-day rest, a 24- hour challenge patch was applied on the original and alternate arm sites.
GLP compliance:
not specified

Test material

Constituent 1
Reference substance name:
C12-LAS
IUPAC Name:
C12-LAS
Details on test material:
LAS; activity: 30.0%

Method

Type of population:
general
Ethical approval:
confirmed, but no further information available
Subjects:
95 volunteers were treated with LAS at 0.10% (w/v) on the upper arms, under occlusive patch conditions.
Route of administration:
dermal
Details on study design:
LAS was applied at 0.10% (w/v) on the upper arms of volunteers, under occlusive patch conditions. Test material was applied for 24 hours, 3 times a
week, for 3 weeks during the induction period. After a 14-17-day rest, a 24- hour challenge patch was applied on the original and alternate arm sites.

Results and discussion

Results of examinations:
There was no evidence of skin sensitization on the 95 subjects who completed the test.

Applicant's summary and conclusion

Conclusions:
95 volunteers were treated with LAS at 0.10% (w/v) on the upper arms, under occlusive patch conditions. Test material was applied for 24 hours, 3 times a week, for 3 weeks during the induction period. After a 14- to 17-day rest, a 24-hour challenge patch was applied on the original and alternate arm sites.
There was no evidence of skin sensitisation on the 95 subjects who completed the test.
Executive summary:

95 volunteers were treated with LAS at 0.10% (w/v) on the upper arms, under occlusive patch conditions. Test material was applied for 24 hours, 3 times a week, for 3 weeks during the induction period. After a 14- to 17-day rest, a 24-hour challenge patch was applied on the original and alternate arm sites.

There was no evidence of skin sensitisation on the 95 subjects who completed the test.